A Phase 1b, Multicenter, Open-Label Study of DSP 7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Atezolizumab in Adult Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1b, Multicenter, Open-Label Study of DSP 7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Atezolizumab in Adult Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Adegramotide/nelatimotide (Primary) ; Atezolizumab; Nivolumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 03 Apr 2018 Planned primary completion date changed from 1 May 2018 to 1 Oct 2018.
    • 21 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 21 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top